Business Wire

TRUEBLUE

Share
Trueblue Announces Integration with Microsoft Dynamics 365 to Enhance Customer Engagement in the Life Sciences Market

Trueblue is making the digital working model of pharmaceutical and life sciences companies more accessible. Trueblue announces the integration of its Artificial Intelligence Relationship Management (AiRM) with Microsoft Dynamics 365 and Power Platform to enhance the customer experience for the pharmaceutical and life sciences market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005613/en/

AiRM is the evolution of Customer Relationship Management (CRM), where AI is the foundation that powers operational and analytical solutions based on Microsoft Dynamics 365. Its native ability to integrate data from multiple sources provides a 360 degree customer view that allows the implementation of a truly omni-channel strategy. Coupled with M.A.R.C. (My Artificial Intelligence Companion) , Trueblue’s intelligent and virtual assistant, the result is a dramatically simplified access to information by means of a fully conversational interaction through smartphones and portable devices.

"I'm excited about this relationship. Microsoft is the ideal partner for us", states Marco Bonesini, CEO & President of Trueblue. "Thanks to its innovative technological solutions, global infrastructure and market leadership with worldwide service coverage, Microsoft enables us to realize our vision of a unique system in which AI is natively integrated with operational and analytical areas, empowering and facilitating the customer engagement with information at your fingertips".

The goal of this integration is to give customers the most advanced technology on the market, giving them the opportunity – through AiRM – to manage and interact in the simplest and most innovative ways, thus revolutionizing multichannel customer engagement using Microsoft platforms and Trueblue’s expertise in the pharma market.

“Never before have life sciences and pharmaceuticals been more important for the world, so we welcome Trueblue to Microsoft’s Business Applications ecosystem as part of the ISV Connect program,” said Steven Guggenheimer, Corporate Vice President . “Trueblue has integrated its solutions for the life sciences and pharmaceutical industry with Dynamics 365 and the Power Platform. This integration will create more choice in the market and increase customer value in this industry.”

About Trueblue

Trueblue provides industry leading cloud-based, ready-to-use BI and AI solutions for the Life Science market.

For more than 20 years Trueblue has been supporting the main multinational Pharma Companies by creating and bringing innovative technology solutions that drive continuous business improvement.

Our unique and holistic understanding of the global data footprint, together with our deep industry knowledge and genuine Customer Experience focus, gives us the ability to co-create disruptive and effective solutions that are quickly adopted by the final users and have been, year after year, recognized by industry leading advisory firms (e.g. Gartner).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Second Quarter and First Half 2025 Earnings19.9.2025 14:30:00 CEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2025 results on Friday, September 26, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 11:00 a.m. EDT, 4:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2025 results at 12:00 p.m. EDT, 5:00 p.m. Morocco and London time (GMT+1) on Friday, September 26, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc

GCCA Concrete in Life Global Photography Competition Launches19.9.2025 14:00:00 CEST | Press release

Tens of thousands of entries expected, focusing on concrete's essential role Overall winner of the free-to-enter competition will receive top prize of $10,000 USD With category prizes of $2,500 USD across each theme This year’s Concrete in Life, a popular global photography competition which celebrates the essential role of concrete across the world, has been officially launched. Now in its 7th year, the competition which receives tens of thousands of entries every year from every corner of the world, highlights the sustainability, versatility, beauty and durable presence of the world’s most used material after water. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919202417/en/ Overall Winner, Concrete in Life 2024/25, Venice Beach Skating by Henrik Hagerup, Venice Beach, Los Angeles, USA Run by the Global Cement and Concrete Association (GCCA), the competition is open to everyone - professionals, amateurs, or anyone with

European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively19.9.2025 12:00:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL,biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919502394/en/ “The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.3,4 “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to im

Cluster Reply Supports Riverty’s AI-first Strategy for Omnichannel,Human-centric Customer Service19.9.2025 11:15:00 CEST | Press release

Cluster Reply, the Reply company specialised in digital platform solutions leveraging Microsoft technologies, has partnered with fintech company Riverty to accelerate the rollout of a pioneering customer service platform – delivered in record time of just 100 days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919101836/en/ The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The platform leverages Microsoft Dynamics 365 Custom

L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release

With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye